Download PDF
Thromb Haemost 2018; 118(11): 1867-1874
DOI: 10.1055/s-0038-1673685
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Mutational Epidemiology of Congenital Fibrinogen Disorders

Alessandro Casini
1   Division of Angiology and Haemostasis, Faculty of Medicine, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland
,
Marc Blondon
1   Division of Angiology and Haemostasis, Faculty of Medicine, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland
,
Veronique Tintillier
2   Institut Hématologie Transfusion, Pôle Biologie Pathologie Génétique, CHRU, Lille, France
,
Matthew Goodyer
3   Department of Haematology, Institut Central des Hôpitaux, Sion, Switzerland
,
Melike E. Sezgin
4   Department of Pediatric Hematology and Oncology, Uludag University, Bursa, Turkey
,
Adalet M. Gunes
4   Department of Pediatric Hematology and Oncology, Uludag University, Bursa, Turkey
,
Michel Hanss
5   Laboratoire d'Hématologie, Hospices Civils de Lyon, CBPE, Lyon, France
,
Philippe de Moerloose
6   Faculty of Medicine, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland
,
Marguerite Neerman-Arbez
7   Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland
› Author Affiliations Funding This project was supported by the Swiss National Science Foundation (grants #31003A-152633/I and #31003A_172864) and an unrestricted grant from the ISTH2007 Presidential Fund.
Further Information

Publication History

12 May 2018

02 September 2018

Publication Date:
17 October 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background Numerous mutations in FGA, FGB or FGG lead to congenital fibrinogen disorders (CFDs), but their epidemiology is not well characterized. The aim of this study was to evaluate the molecular epidemiology of CFD and to develop a genotyping strategy.

Methods Genetic data from 266 unrelated CFD patients genotyped at our laboratory and from a CFD open access database (n = 1,142) were evaluated. We developed a step-wise screening strategy for the molecular diagnosis of CFD and prospectively tested this strategy on 32 consecutive CFD probands.

Results We identified 345 mutated alleles overall, among 187 heterozygous, 63 homozygous and 16 compound heterozygous individuals. Afibrinogenemia was almost always caused by null mutations (98.6%), mainly in FGA (85%). Hypofibrinogenemia was mainly caused by missense mutations of FGB or FGG (54.2%). Dysfibrinogenemia was almost always caused by heterozygous missense mutations (99.3%) in FGA and FGG. Hotspot mutations were prevalent among quantitative (33.1%) and qualitative fibrinogen disorders (71.1%). The mutational cluster at our laboratory was similar with that reported in the CFD open access database. The proposed step-wise genetic screening strategy proved efficient in both the development and validation samples for CFD: the screening of FGA exons 2, 4, 5 and FGG exon 8 and search for the 11 kb deletion of FGA led to the identification of approximately 80% of mutated alleles, including 15 new mutations.

Conclusion The described molecular epidemiology of CFD is complex. The proposed step-wise genetic screening strategy may provide an efficient way to identify causative mutations analysing a minimal number of exons.

Keywords

afibrinogenemia - congenital - hypofibrinogenemia - dysfibrinogenemia - hypodysfibrinogenaemia - mutation

Authors' Contributions

A. Casini, P. de Moerloose and M. Neerman-Arbez designed the research and wrote the article; A. Casini and M. Blondon extracted and analysed the data; A. Casini and M. Neerman-Arbez performed genetic analyses; M. Hanss provided data from the Human Fibrinogen Database; and V. Tintillier, M. Goodyer, A. Meral and M. Evim provided genetic samples and patients information (more than two patients in the prospective part of the study). All authors provided critical revisions to the manuscript.


Supplementary Material

 

  • References

  • 1 Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost 2016; 42 (04) 366-374
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost 2016; 42 (04) 356-365
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125 (13) 2052-2061
    CrossrefPubMedSearch in Google Scholar
  • 4 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4 (10) 2115-2129
    CrossrefPubMedSearch in Google Scholar
  • 5 Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90
    CrossrefPubMedSearch in Google Scholar
  • 6 Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 5 (Suppl. 01) 125-131
    CrossrefPubMedSearch in Google Scholar
  • 7 Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 2015; 13 (06) 909-919
    CrossrefPubMedSearch in Google Scholar
  • 8 Paraboschi EM, Duga S, Asselta R. Fibrinogen as a pleiotropic protein causing human diseases: the mutational burden of Aα, Bβ, and γ chains. Int J Mol Sci 2017; 18 (12) 2711-2726
    CrossrefPubMedSearch in Google Scholar
  • 9 Neerman-Arbez M, de Moerloose P, Bridel C. , et al. Mutations in the fibrinogen aalpha gene account for the majority of cases of congenital afibrinogenemia. Blood 2000; 96 (01) 149-152
    PubMedSearch in Google Scholar
  • 10 Vu D, Bolton-Maggs PH, Parr JR, Morris MA, de Moerloose P, Neerman-Arbez M. Congenital afibrinogenemia: identification and expression of a missense mutation in FGB impairing fibrinogen secretion. Blood 2003; 102 (13) 4413-4415
    CrossrefPubMedSearch in Google Scholar
  • 11 Casini A, Lukowski S, Quintard VL. , et al. FGB mutations leading to congenital quantitative fibrinogen deficiencies: an update and report of four novel mutations. Thromb Res 2014; 133 (05) 868-874
    CrossrefPubMedSearch in Google Scholar
  • 12 Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM. Novel fibrinogen gamma375 Arg-->Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36 (03) 652-658
    CrossrefPubMedSearch in Google Scholar
  • 13 Dib N, Quelin F, Ternisien C. , et al. Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost 2007; 5 (10) 1999-2005
    CrossrefPubMedSearch in Google Scholar
  • 14 Galanakis DK, Neerman-Arbez M, Scheiner T. , et al. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release. Blood Coagul Fibrinolysis 2007; 18 (08) 731-737
    CrossrefPubMedSearch in Google Scholar
  • 15 Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14 (06) 1151-1158
    CrossrefPubMedSearch in Google Scholar
  • 16 Neerman-Arbez M, de Moerloose P, Honsberger A. , et al. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes. Hum Genet 2001; 108 (03) 237-240
    CrossrefPubMedSearch in Google Scholar
  • 17 Asselta R, Platè M, Robusto M. , et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost 2015; 113 (03) 567-576
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Casini A, Blondon M, Lebreton A. , et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125 (03) 553-561
    CrossrefPubMedSearch in Google Scholar
  • 19 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73 (01) 151-161
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Sivapalaratnam S, Collins J, Gomez K. Diagnosis of inherited bleeding disorders in the genomic era. Br J Haematol 2017; 179 (03) 363-376
    CrossrefPubMedSearch in Google Scholar
  • 21 Fernández-Cadenas I, Penalba A, Boada C. , et al. Exome sequencing and clot lysis experiments demonstrate the R458C mutation of the alpha chain of fibrinogen to be associated with impaired fibrinolysis in a family with thrombophilia. J Atheroscler Thromb 2016; 23 (04) 431-440
    CrossrefPubMedSearch in Google Scholar
  • 22 Mukai S, Nagata K, Ikeda M. , et al. Genetic analyses of novel compound heterozygous hypodysfibrinogenemia, Tsukuba I: FGG c.1129+62_65 del AATA and FGG c.1299+4 del A. Thromb Res 2016; 148: 111-117
    CrossrefPubMedSearch in Google Scholar